title: New generation adjuvants--from empiricism to rational design.
abstract: Adjuvants are an essential component of modern vaccine development. Despite many decades of development, only a few types of adjuvants are currently included in vaccines approved for human use. In order to better understand the reasons that development of some adjuvants succeeded while many others failed, we discuss some of the common attributes of successful first generation adjuvants. Next, we evaluate current trends in the development of second generation adjuvants, including the potential advantages of rationally designed synthetic immune potentiators appropriately formulated. Finally, we discuss desirable attributes of next generation adjuvants. Throughout, we emphasize that the importance of formulation and analytical characterization in all aspects of vaccine adjuvant development is often underappreciated. We highlight the formulation factors that must be evaluated in order to optimize interactions between vaccine antigens, immune potentiators, and particulate formulations, and the resulting effects on safety, biological activity, manufacturability, and stability.
authors.affiliation: Novartis Vaccines, Cambridge, MA, United States.
authors.forename: Derek T
authors.initials: DT
authors.lastname: O'Hagan
authors.affiliation: IDRI, Seattle, WA, United States. Electronic address: cfox@idri.org.
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Fox
mesh_terms: D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000302:isolation & purification* / Q000494:pharmacology*; D000818:Animals; D015195:Drug Design; D055808:Drug Discovery / Q000379:methods*; D019348:Empiricism; D006801:Humans
chemical_list: D000276:Adjuvants, Immunologic
keywords: Alum; Emulsion; Formulation; MPL; Vaccine adjuvant